Issues and promises of bevacizumab in prostate cancer treatment

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics 2012. CA Cancer J Clin. 2015;65(2):87–108.
   PubMed Web of Science ®Google Scholar
• Nelson PS. Molecular states underlying androgen receptoractivation: a framework for therapeutics targeting androgen signalling in prostate cancer. J Clin Oncol. 2012;30(6):644–646.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186.
   PubMed Web of Science ®Google Scholar
• Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17(11):1359–1370.
   PubMed Web of Science ®Google Scholar
• Jayson GC, Kerbel R, Ellis LM, et al. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 2016;388(10043):518–529.
   PubMed Web of Science ®Google Scholar
• Borre M, Offersen BV, Nerstrom B, et al. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. BR J Cancer. 1998;78(7):940–944.
   PubMed Web of Science ®Google Scholar
• Ferrer FA, Miller LJ, Andrawis RI, et al. Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. J Urol. 1997;157(6):2329–2333.
   PubMed Web of Science ®Google Scholar
• De Brot S, Ntkeim A, Cardenas R, et al. Regulation of vascular endothelial growth factor in prostate cancer. EndocrRelat Cancer. 2015;22(3):R107–23.
   PubMed Web of Science ®Google Scholar
• Gustavsson H, Welen K, Damber J-E. Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate. 2005;62(4):364–373.
   PubMed Web of Science ®Google Scholar
• Burton JB, Priceman SJ, Sung JL, et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Research. 2008;68(19):7828–7837.
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–827.
   PubMed Web of Science ®Google Scholar
• Bok RA, Halabi S, Fei DT, et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001;61(6):2533–2536.
   PubMed Web of Science ®Google Scholar
• George DJ, Halabi S, Shepard TF, et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia group B 9480. Clin Cancer Res. 2001;7(7):1932–1936.
   PubMed Web of Science ®Google Scholar
• Shariat SF, Amwuri VA, Lamb DJ, et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol. 2004;22(9):1655–1663.
   PubMed Web of Science ®Google Scholar
• Morrissey C, Dowell A, Koreckij TD, et al. Inhibition of angiopoietin-2 in LuCap 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate. 2010;70(16):1799–1808.
   PubMed Web of Science ®Google Scholar
• Huss WJ, Barrios RJ, Foster BA, et al. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate. 2013;54(1):8–16.
   Google Scholar
• Wedel S, Hudak L, Seibel JM, et al. Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. Cancer Lett. 2011;301(1):17–28.
   PubMed Web of Science ®Google Scholar
• Sieveking DP, Lim P, Chow RW, et al. A sex-specific role for androgens in angiogenesis. J Exp Med. 2010;207(2):345–352.
   PubMed Web of Science ®Google Scholar
• Huang CN, Huang SP, Pao JB, et al. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol. 2012;23(3):707–713.
   PubMed Web of Science ®Google Scholar
• Stewart RJ, Panigrahy D, Flynn E, et al. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol. 2001;165(2):688–693.
   PubMed Web of Science ®Google Scholar
• Boddy JL, Fox SB, Han C, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a and prolyl hydroxyolases in human prostate cancer. Clin Cancer Res. 2005;11(21):7658–7663.
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Carducci MA. Targeting angiogenesis for the treatment of prostate cancer. Expert Opin Ther Targets. 2012;16(4):365–376.
   PubMed Web of Science ®Google Scholar
• Presta LG, Chen H, O’Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593–4599.
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362(6423):841–844.
   PubMed Web of Science ®Google Scholar
• Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65(3):671–680.
   PubMed Web of Science ®Google Scholar
• Fox WD, Higgins B, Malese KM, et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res. 2002;8(10):3226–3231.
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19(3):843–850.
   PubMed Web of Science ®Google Scholar
• Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19(3):851–856.
   PubMed Web of Science ®Google Scholar
• Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist. 2010;15(8):819–825.
   PubMed Web of Science ®Google Scholar
• Verheul HM, Lolkema MP, Qian DZ, et al. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res. 2007;13(18 Pt 1):5341–5347.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study. J Clin Oncol. 2008;26(33):5326–5334.
   PubMed Web of Science ®Google Scholar
• Reese DM, Fratesi P, Corry M, et al. A Phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. The Prostate Journal. 2002;3(2):65–70.
   Google Scholar
• Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol. 2008;54(5):1089–1096.
   PubMed Web of Science ®Google Scholar
• Francini F, Pascucci A, Francini E, et al. Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel. Prostate Cancer. 2011;2011:258689.
   PubMedGoogle Scholar
• Picus J, Halabi S, Kelly WK, et al. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from cancer and leukemia group B study 90006. Cancer. 2011;117(3):526–533.
   PubMed Web of Science ®Google Scholar
• Pienta KJ. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer. Semin Oncol. 2001;28(4 Suppl 15):3–7.
   PubMed Web of Science ®Google Scholar
• Petrylak D, Tangen C, Hussain M, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. NEJM. 2004;351(15):1513–1520.
   PubMed Web of Science ®Google Scholar
• Tannock I, de Wit R, Berry W, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1515.
   PubMed Web of Science ®Google Scholar
• Kelly WK, Halabi S, Hars V, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30(13):1534–1540.
   PubMed Web of Science ®Google Scholar
• Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(12):2070–2076.
   PubMed Web of Science ®Google Scholar
• Madan RA, Karzai FH, Ning YM, et al. Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer. BJU Int. 2016;118(4):590–597.
   PubMed Web of Science ®Google Scholar
• Ryan CJ, Smith MR, De Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138–148.
   PubMed Web of Science ®Google Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–433.
   PubMed Web of Science ®Google Scholar
• Vaishampayan UN, Fontana J, Heilbrun LK, et al. Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. Urol Oncol. 2014;32(1):31.e25–33.
   PubMed Web of Science ®Google Scholar
• Gross ME, Dorff TB, Quinn DI, et al. Safety and efficacy of docetaxel, bevacizumab, and everolimus for castration-resistant prostate cancer (CRPC). Clin Genitourin Cancer. 2017;S1558–7673(17):30200–30208. Epub ahead of print.
   Google Scholar
• Ogita S, Tejwani S, Heilbrun L, et al. Pilot phase II of bevacizumab monotherapy in non metastatic castrate-resistant prostate cancer. ISRN Oncol. 2012;2012:242850.
   PubMedGoogle Scholar
• Rini BI, Weinberg W, Fong L, et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006;107(1):67–74.
   PubMed Web of Science ®Google Scholar
• Vuky J, Pham HT, Warren S, et al. Phase II study of long-term androgen suppression with bevacizumab and intensity-modulated radiation therapy (IMRT) in high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2012;82(4):e609–15.
   PubMed Web of Science ®Google Scholar
• Ross RW, Galsky MD, Febbo P, et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a prostate cancer clinical trials consortium trial. Cancer. 2012;118(19):4777–4784.
   PubMed Web of Science ®Google Scholar
• Febbo PG, Richie JP, George DJ, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localize prostate cancer. Clin Cancer Res. 2005;11(14):5233–5240.
   PubMed Web of Science ®Google Scholar
• Mackay RR, Gray KP, Hayes JH, et al. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer. Cancer. 2015;121(15):2603–2611.
   PubMed Web of Science ®Google Scholar
• Nakabayashi M, Xie W, Buckle G, et al. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013;81(3):611–616.
   PubMed Web of Science ®Google Scholar
• Mckay RR, Zurita AJ, Werner L, et al. A randomized phase II trial of short-course androgen deprivation therapy with or without bevacizumab for patients with recurrent prostate cancer after definitive local therapy. J Clin Oncol. 2016;34(16):1913–1920.
   PubMed Web of Science ®Google Scholar
• Cortes J, Calvo V, Ramírez-Merino N, et al. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol. 2012;23(5):1130–1137.
   PubMed Web of Science ®Google Scholar
• Sher A, Wu S. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy – a meta-analysis. Acta Oncol. 2011;50(7):997–1005.
   PubMed Web of Science ®Google Scholar
• Patel JN, Jiang C, Hertz DL, et al. Bevacizumab and risk of arterial and venous thromboembolism in metastatic castration-resistant prostate cancer patients treated on Cancer and Leukemia group B (CALGB) 90401 (Alliance). Cancer. 2015;121(7):1025–1031.
   PubMed Web of Science ®Google Scholar
• Ranpura V, Pulipati B, Chu D, et al. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23(5):460–468.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Wright JD, Lim E, et al. Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. J Clin Oncol. 2013;31(28):3592–3599.
   PubMed Web of Science ®Google Scholar
• Corn PG, Wang F, McKeehan WL, et al. Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res. 2013;19(21):5856–5866.
   PubMed Web of Science ®Google Scholar
• Kozloff MF, Berlin J, Flynn PJ, et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology. 2010;78(5–6):329–339.
   PubMed Web of Science ®Google Scholar
• Gray R, Bhattacharya S, Bowden C, et al. Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. J Clin Oncol. 2009;27(30):4966–4972.
   PubMed Web of Science ®Google Scholar
• Eisermann K, Broderick CJ, Bazarov A, et al. Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer. 2013;12:7.
   PubMed Web of Science ®Google Scholar
• Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 2006;13(3):739–749.
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ, Willard MT, Frederickson CE, et al. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3ʹ-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res. 2003;9(7):2416–2425.
   PubMed Web of Science ®Google Scholar
• Steiner H, Berger AP, Godoy-Tundidor S, et al. An autocrine loop of vascular endothelial growth factor is established in prostate cancer cells generated after prolonged treatment with interleukin 6. Eur J Cancer. 2004;40(7):1066–1072.
   PubMed Web of Science ®Google Scholar
• Fernandez EV, Reece KM, Ley AM, et al. Dual targeting of the androgen receptor and hypoxia-inducible factor 1α pathways synergistically inhibits castration-resistant prostate cancer cells. Mol Pharmacol. 2015;87(6):1006–1012.
   PubMed Web of Science ®Google Scholar